[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

China Generics Market to Surpass USA in Terms of Sales by 2017, States Aruvian’s R’search in Its Report Available at MarketPublishers.com

10 Apr 2017 • by Natalie Aster

LONDON – China’s pharmaceutical industry is poised to grow from a value of USD 108 billion to amount to USD 167 billion by end-2020, representing a 9.1% CAGR. Generics represent an essential segment of the nation’s pharmaceutical sector and the governmental policies are aimed at giving a boost to the generics marketplace. The Chinese generic marketplace is anticipated to surpass the USA with respect to sales by 2017-end.

The domestic generics industry has been gaining traction at a significantly robust pace in the recent past, even though the overall pharmaceutical market has reached a saturation point. Generics currently captures 90% of the total Chinese pharma industry, with the pattern of fast-paced growth anticipated to keep on through to 2020.

As the government heads towards making generic drugs affordable for all walks of society, many dominant drug developers of the world are coming into the Chinese market as they don't have to absorb the investment costs over against manufacturers of novel drugs.

Sanofi SA, Mylan, China Grand Pharmaceutical and Healthcare Holdings Limited, Cipla Limited, Teva Pharmaceutical Industries, and Sandoz International are some of the leading players in the marketplace.

Topical research report “Analyzing Generics Market in China 2017” drawn up by Aruvian’s R’search presents an unbiased, detailed analysis of the market for generic drugs on a national level.

The study takes a comprehensive review of the industry spanning from 2012 through to 2021; analyses the market in terms of volume and value, provides industry segmentation based on geography; and includes granular forecasts of the industry development. The generics industry across APAC is also included. Porter’s five forces analysis of the industry is included, as well. The report casts light on the generics pricing and reimbursement landscape in the country, alongside limelighting trends and challenges that the industry is facing. The research provides all-round information on the 6 major companies operating in the marketplace through an analysis of business segments, financial information, and a granular SWOT analysis. 

More in-demand studies by the publisher can be found at Aruvian’s R’search page.


The Market Publishers, Ltd.
Natalie Aster
Tel: +44 208 144 6009
Fax: +44 207 900 3970
[email protected]

Analytics & News

Weekly Digest